Acrivon Therapeutics
(NASDAQ:ACRV)
$10.54
0.20[1.93%]
At close: Apr 18
$10.54
0[0.00%]
After Hours: 4:00PM EDT
Consensus Rating1
Buy
Highest Price Target1
$26.00
Lowest Price Target1
$14.00
Consensus Price Target1
$18.30

Acrivon Therapeutics Stock (NASDAQ:ACRV), Analyst Ratings, Price Targets, Predictions

Acrivon Therapeutics Inc has a consensus price target of $18.3, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from Ladenburg Thalmann, BMO Capital, and JMP Securities on April 5, 2024, April 1, 2024, and April 1, 2024. With an average price target of $15.33 between Ladenburg Thalmann, BMO Capital, and JMP Securities, there's an implied 45.48% upside for Acrivon Therapeutics Inc from these 3 analyst ratings.

Analyst Trend
1
Nov 23
1
Mar
2
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Ladenburg Thalmann
BMO Capital
JMP Securities
HC Wainwright & Co.
Maxim Group

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Acrivon Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
04/05/2024ACRVBuy Now
Acrivon Therapeutics
$10.5432.83%Ladenburg Thalmann
Aydin Huseynov
$18 → $14MaintainsBuyGet Alert
04/01/2024ACRVBuy Now
Acrivon Therapeutics
$10.5470.78%BMO Capital
Etzer Darout
→ $18ReiteratesOutperform → OutperformGet Alert
04/01/2024ACRVBuy Now
Acrivon Therapeutics
$10.5432.83%JMP Securities
Silvan Tuerkcan
→ $14ReiteratesMarket Outperform → Market OutperformGet Alert
03/28/2024ACRVBuy Now
Acrivon Therapeutics
$10.5489.75%HC Wainwright & Co.
Emily Bodnar
→ $20ReiteratesBuy → BuyGet Alert
03/01/2024ACRVBuy Now
Acrivon Therapeutics
$10.5432.83%JMP Securities
Silvan Tuerkcan
→ $14Initiates → Market OutperformGet Alert
11/10/2023ACRVBuy Now
Acrivon Therapeutics
$10.54127.7%BMO Capital
Etzer Darout
$25 → $24MaintainsOutperformGet Alert
10/05/2023ACRVBuy Now
Acrivon Therapeutics
$10.54127.7%Maxim Group
Michael Okunewitch
→ $24Initiates → BuyGet Alert
09/06/2023ACRVBuy Now
Acrivon Therapeutics
$10.5489.75%HC Wainwright & Co.
Emily Bodnar
→ $20ReiteratesBuy → BuyGet Alert
08/18/2023ACRVBuy Now
Acrivon Therapeutics
$10.54146.68%JonesTrading
Soumit Roy
→ $26Initiates → BuyGet Alert
08/11/2023ACRVBuy Now
Acrivon Therapeutics
$10.5489.75%HC Wainwright & Co.
Emily Bodnar
$21 → $20ReiteratesBuy → BuyGet Alert
06/02/2023ACRVBuy Now
Acrivon Therapeutics
$10.54137.19%Oppenheimer
Matthew Biegler
→ $25Initiates → OutperformGet Alert
05/08/2023ACRVBuy Now
Acrivon Therapeutics
$10.54137.19%BMO Capital
Etzer Darout
→ $25Initiates → OutperformGet Alert
05/02/2023ACRVBuy Now
Acrivon Therapeutics
$10.54127.7%HC Wainwright & Co.
Emily Bodnar
→ $24Reiterates → BuyGet Alert
04/20/2023ACRVBuy Now
Acrivon Therapeutics
$10.54127.7%HC Wainwright & Co.
Emily Bodnar
→ $24Initiates → BuyGet Alert
12/12/2022ACRVBuy Now
Acrivon Therapeutics
$10.54Cowen & Co.
Joseph Thome
Initiates → OutperformGet Alert
12/12/2022ACRVBuy Now
Acrivon Therapeutics
$10.5461.29%Jefferies
Akash Tewari
→ $17Initiates → BuyGet Alert
12/12/2022ACRVBuy Now
Acrivon Therapeutics
$10.54137.19%Piper Sandler
Joseph Catanzaro
→ $25Initiates → OverweightGet Alert

FAQ

Q

What is the target price for Acrivon Therapeutics (ACRV)?

A

The latest price target for Acrivon Therapeutics (NASDAQ: ACRV) was reported by Ladenburg Thalmann on April 5, 2024. The analyst firm set a price target for $14.00 expecting ACRV to rise to within 12 months (a possible 32.83% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Acrivon Therapeutics (ACRV)?

A

The latest analyst rating for Acrivon Therapeutics (NASDAQ: ACRV) was provided by Ladenburg Thalmann, and Acrivon Therapeutics maintained their buy rating.

Q

When was the last upgrade for Acrivon Therapeutics (ACRV)?

A

There is no last upgrade for Acrivon Therapeutics.

Q

When was the last downgrade for Acrivon Therapeutics (ACRV)?

A

There is no last downgrade for Acrivon Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Acrivon Therapeutics (ACRV)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acrivon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acrivon Therapeutics was filed on April 5, 2024 so you should expect the next rating to be made available sometime around April 5, 2025.

Q

Is the Analyst Rating Acrivon Therapeutics (ACRV) correct?

A

While ratings are subjective and will change, the latest Acrivon Therapeutics (ACRV) rating was a maintained with a price target of $18.00 to $14.00. The current price Acrivon Therapeutics (ACRV) is trading at is $10.54, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch